(VIANEWS) – The NASDAQ opens in less than one hour and Xenetic Biosciences‘s pre-market value is already 5.32% down.
Xenetic Biosciences’s last close was $0.63, 49.28% below its 52-week high of $1.25.
The last session, NASDAQ finished with Xenetic Biosciences (XBIO) rising 3.93% to $0.63. NASDAQ dropped 1.68% to $11,910.52, following the last session’s downward trend on what was an all-around negative trend exchanging session.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.34%.
Sales Growth
Xenetic Biosciences’s sales growth for the next quarter is negative 27.9%.
Yearly Top and Bottom Value
Xenetic Biosciences’s stock is valued at $0.63 at 08:57 EST, way under its 52-week high of $1.25 and way above its 52-week low of $0.24.
More news about Xenetic Biosciences (XBIO).
